Corporate News 04-Jan-23
Gland Pharma's Dundigal facility receives EIR report from USFDA
Gland Pharma announced that following the Pre-Market Inspection covering US FDA's Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) at the Company's Dundigal Facility at Hyderabad from 22 August 2022 to 25 August 2022; the Company has received the Establishment Inspection Report (EIR) from the Office of Product Evaluation and Quality Center for Devices and Radiological Health, US FDA indicating closure of the inspection.
Previous News
Gland Pharma
( Results - Analysis 23-May-24 10:29 )
Gland Pharma
( Results - Analysis 15-Feb-24 11:08 )
Gland Pharma consolidated net profit declines 34.64% in the June 2022 quarter
( Results - Announcements 20-Jul-22 17:47 )
Gland Pharma Ltd gains for third straight session
( Hot Pursuit - 20-Dec-23 13:05 )
Gland Pharma Q1 PAT drops 35% YoY to Rs 229 cr
( Hot Pursuit - 20-Jul-22 17:47 )
Gland Pharma Ltd down for fifth straight session
( Hot Pursuit - 13-Jul-22 13:35 )
Gland Pharma IPO subscribed 22%
( IPO Centre - IPO News 10-Nov-20 17:34 )
Gland Pharma to announce Quarterly Result
( Corporate News - 30-Jun-21 12:43 )
Gland Pharma Q3 PAT slides 15% YoY to Rs 232 cr
( Hot Pursuit - 24-Jan-23 09:43 )
Gland Pharma to hold AGM
( Corporate News - 23-May-24 09:38 )
Gland Pharma
( Results - Analysis 27-Oct-22 10:43 )
Other Stories
Tridhya Tech to convene board meeting
03-Jul-24 20:06
Sonu Infratech schedules EGM
03-Jul-24 19:59
Sakuma Exports to convene AGM
03-Jul-24 19:59
Time Technoplast repays commercial paper
03-Jul-24 18:31
Board of Aditya Vision approves stock split and listing of share on NSE
03-Jul-24 18:24
Pricol director resigns
03-Jul-24 18:21
Board of VMS Industries recommends first interim dividend
03-Jul-24 17:49
Lakshmi Machine Works to declare Quarterly Result
03-Jul-24 17:44
Modison to convene AGM
03-Jul-24 17:43
Sybly Industries to discuss results
03-Jul-24 17:43
Back
Top
